Actinium Pharmaceuticals, Inc. (ATNM) Free cash flow 2016–2025
Actinium Pharmaceuticals, Inc. (ATNM) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$24.7MFY2025 · since FY2016: -$20.8M → -$24.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$24.7M | +25.4% |
| FY2024 | -$33.1M | +30.3% |
| FY2023 | -$47.5M | -673.7% |
| FY2022 | $8.3M | +139.4% |
| FY2021 | -$21.0M | +4.0% |
| FY2020 | -$21.9M | -1.6% |
| FY2019 | -$21.5M | -4.2% |
| FY2018 | -$20.7M | +4.2% |
| FY2017 | -$21.6M | -3.5% |
| FY2016 | -$20.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ATNM financial trends
ATNM RevenueATNM Net incomeATNM Net marginATNM Gross profitATNM Gross marginATNM Operating incomeATNM Operating marginATNM Operating cash flowATNM Capital expendituresATNM Return on equityATNM Stock buybacksATNM Dividends paidATNM Total assetsATNM Total liabilitiesATNM Shareholders’ equityATNM overview →